Prospects for antihistamines in the treatment of asthma

Nelson, Harold S.

doi:10.1016/s0091-6749(03)01883-9

Cited by 47 publications

(21 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results suggest the inhibitory effect of T. cordifolia in anaphylaxis. The role of histamine in asthma disease is well established (Nelson, 2003). The present study indicates that administration of T. cordifolia can reduce the histamine induced bronchospasm.…”

Section: Discussionsupporting

confidence: 65%

The protective effect ofTinospora cordifoliaon various mast cell mediated allergic reactions

Zalawadia

Gandhi

Patel

et al. 2009

Pharmaceutical Biology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 65%

The protective effect ofTinospora cordifoliaon various mast cell mediated allergic reactions

Zalawadia

Gandhi

Patel

et al. 2009

Pharmaceutical Biology

View full text Add to dashboard Cite

“…Desloratadine, fexofenadine, cetirizine and levocetirizine have modest effects on nasal blockage [60][61][62][63][64][65]. Improve allergic symptoms at sites other than the nose such as the conjunctiva, palate, skin and lower airways [66][67][68]. Regular therapy is more effective than 'as-needed' use in persistent rhinitis [69].…”

Section: (All Have a Grade Of Recommendation = A)mentioning

confidence: 99%

BSACI guidelines for the management of allergic and non‐allergic rhinitis

Scadding

Durham

Mirakian

et al. 2007

Clin Experimental Allergy

349

292

View full text Add to dashboard Cite

SummaryThis guidance for the management of patients with allergic and non-allergic rhinitis has been prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI). The guideline is based on evidence as well as on expert opinion and is for use by both adult physicians and paediatricians practicing in allergy. The recommendations are evidence graded. During the development of these guidelines, all BSACI members were included in the consultation process using a web-based system. Their comments and suggestions were carefully considered by the SOCC. Where evidence was lacking, consensus was reached by the experts on the committee. Included in this guideline are clinical classification of rhinitis, aetiology, diagnosis, investigations and management including subcutaneous and sublingual immunotherapy. There are also special sections for children, co-morbid associations and pregnancy. Finally, we have made recommendations for potential areas of future research.

show abstract

“…It is triggered by exposure of allergen, irritants, cold air or exercise which releases the inflammatory mediator like histamine, acetylcholine and leukotrines that directly causes the bronchospasm. [34,35] Exposure of histamine aerosol (1% w/v) to cause the bronchospasm in the form of PCD in guinea pigs. In our study, we observed that latent period of PCD was significantly increased in AHR-1 treated animals.…”

Section: Discussionmentioning

confidence: 99%

Antianaphylactic, mast cell stabilizing and antiasthmatic activity of AHR-1 (a polyherbal formulation)

Maheshwari¹,

Balaraman²,

Sailor³

et al. 2014

Phcog J.

View full text Add to dashboard Cite

Objective: This work was mainly aimed to study the anti-anaphylactic, mast cell stabilizing and antiasthmatic activity of AHR-1 (a polyherbal formulation) which contain various herbal extracts. Methods: The antianaphylactic activity of AHR-1 was evaluated in rats using active anaphylaxis model.Rats were then observed for onset of symptoms of anaphylaxis reaction such as increased respiratory rate, dyspnea, cyanosis and mortality. Serum IgE, leukocyte, eosinophil countand % polymorphs were calculated. Mast cell stabilizing effect was investigated by in vitro challenge of antigensensitized rat intestinal mesenteries. Antiasthmatic effect was studied in guinea pigs using histamine-induced bronchospasm, in which occurrence of preconvulsive dyspnea (PCD) was noted as end point. Results: Anaphylactic shock caused by intravenous antigen challenge showed 83% mortality with a significant (P<0.001) increase respiratory symptom score.Treatment with AHR-1(250 and 500 mg/kg) reduced the mortality and respiratory symptom score (P<0.05,P<0.001), respectively. AHR-1 (250 and 500 mg/kg) significantly and dose dependently decreased Serum IgE (P<0.05, P<0.001), AEC (P<0.05, P<0.001), total leukocytes (P<0.05, P<0.01) and % polymorphs (P<0.01,P<0.001), respectively as compared to sensitized control group. Sensitized control rats were produced a significant (79%) mesenteric mast cell degranulation, but pre-treatment with AHR-1 (100 and 200µg/ml) produced in a significant (p<0.001) reduction in the number of degranulated mast cells when challenged with horse serum. AHR-1 significantly increased the time of PCD (P<0.001) as compared to control. Conclusion: From these finding, we concluded that AHR-1 is might be effective in treatment various hypersensitivity reactions like anaphylactic shock and asthma.

show abstract

Prospects for antihistamines in the treatment of asthma

Cited by 47 publications

References 41 publications

The protective effect ofTinospora cordifoliaon various mast cell mediated allergic reactions

The protective effect ofTinospora cordifoliaon various mast cell mediated allergic reactions

BSACI guidelines for the management of allergic and non‐allergic rhinitis

Antianaphylactic, mast cell stabilizing and antiasthmatic activity of AHR-1 (a polyherbal formulation)

Contact Info

Product

Resources

About